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Several studies have previously reported propolis, or its constituents, to inhibit tumour angiogenesis. The anti-
angiogenic activity of two Indonesian stingless bee propolis extracts from Sulawesi Island on vascular cells
were assessed. Sample D01 was obtained from the outer side of bee hives, while D02 was from the inner side of
the same hives. The extracts were proﬁled by using liquid chromatography coupled to high resolution mass
spectrometry. The anti-angiogenic capacity was assessed on HUVECs and placenta-derived pericytes by cell
viability, multi-channel wound healing, and CoCl2 based-hypoxia assays. The exact chemical composition has not
been conﬁrmed. The most abundant compounds in Indonesian sample D01 seem to be unusual since they do not
immediately fall into a clear class. Two of the most abundant compounds have elemental compositions matching
actinopyrones. Identiﬁcation on the basis of elemental composition is not deﬁnitive but compounds in D01 are
possibly due to unusually modiﬁed terpenoids. Sample D02 has abundant compounds which include four related
diterpenes with differing degrees of oxygenation and some sesquiterpenes. However, again the proﬁle is unusual.
The anti-angiogenic assays demonstrated that D01 elicited a strong cytotoxic effect and a considerable anti-
migratory activity on the vascular cells. Although D02 demonstrated a much weaker cytotoxic effect on the
cell lines compared to D01, it elicited a substantial protective effect on the pericytes against CoCl2-induced
dropout in an experiment to mimic a micro-environment commonly associated with angiogenesis and tumour
growth. These results demonstrate modulatory effects of these propolis samples in vascular cells, which requires
further investigation.1. Introduction
Among many existing natural products propolis is the most ambig-
uous in terms of the source, as it is derived from both plants and animals.
Propolis is a natural resinous material that honey bees produce by col-
lecting exudates andmaterials of various parts of the plant, such as ﬂower
buds, leaf buds, and tree barks, then mixing them with beeswax and
several bee enzymes (Sforcin and Bankova, 2011). Propolis is charac-
terized as a lipophilic material that is hard, brittle and breakable when
cold but, soft, malleable and considerably adhesive when warm (Mar-
cucci, 1995). It possesses unique herbaceous aromatic scents with various
colorations, including yellow, green, brown, and red (Marcucci, 1995;
Fokt et al., 2010). In nature, propolis is effectively used by honey bees asail.com (M. Iqbal), sahlan@che.u
m 23 April 2019; Accepted 17 Ju
vier Ltd. This is an open access ara protective material as it is attached in many parts of their hive to defend
the colony from predators and pathogens (Umthong et al., 2011). Ina
addition, propolis is beneﬁcial to ﬁx damages in the hive, reﬁne internal
walls, preserve internal heat of the hive, and envelop the corpses of in-
truders that die inside the hive, which forms aseptic cofﬁns and halts the
decay (Bankova et al., 2000).
Generally, propolis contains biochemicals from the class of ﬂavo-
noids, phenolic acid derivatives, cinnamic acids derivatives, terpenes/
terpenoids, tannins, alkaloids and bee enzymes (Xu et al., 2009; Kuma-
zawa et al., 2004). However, due to the nature of propolis, which relates
to its plant origin, the bioactive compounds within propolis of one area
may be different from propolis of another area, depending on the climate,
seasons and environmental conditions (Kujumgiev et al., 1999; Bankovai.ac.id (M. Sahlan).
ne 2019
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sesses. Currently, there are many scientiﬁc reports on the bioactivities of
propolis from both in vitro and in vivo studies, such as anti-viral (in vitro
and animal model in vivo) (Shimizu et al., 2008; Shen et al., 2013;
Bankova et al., 2014), anti-bacterial (in vitro, human model in vivo and ex
vivo) (Velikova et al., 2000; Boisard et al., 2015; Duailibe et al., 2007;
Dziedzic et al., 2013), anti-protozoal (in vitro and animal model in vivo)
(Pontin et al., 2008; Almutairi et al., 2014; Siheri et al., 2014),
anti-inﬂammatory (in vitro, animal model in vivo and ex vivo) (Mirzoeva
and Calder, 1996; Naito et al., 2007), immunomodulatory (in vitro and
animal model in vivo) (Li et al., 2015; Tao et al., 2014), anti-oxidant (in
vitro and animal model in vivo) (Sun et al., 2000; Moreira et al., 2008;
Miguel et al., 2010), cardioprotective (animal model in vivo) (Alyane
et al., 2008; Daleprane and Abdalla, 2013), etc.
Aside from those bioactivities, studies have also shown potential anti-
angiogenic properties of propolis and its pure compounds through mul-
tiple cellular signaling pathways due to the synergistic contributions of
different phytochemicals (Daleprane and Abdalla, 2013). Kunimasa et al.
(2011) reported that the ethanolic extract of Brazilian brown propolis
promoted an inactivation of extracellular signal–regulated kinases ½
(ERK1/2), an activation of caspase-3 and cleavage of poly ADP-ribose
polymerase (PARP) and lamin A/C in an in vitro study, which are all
responsible for cell apoptosis. Some propolis crude samples and pure
compounds have been shown as evident to suppress angiogenesis by
inhibiting vascular endothelial cell growth factor (VEGF) expression (e.g.
the ethanolic extract of Chinese red propolis in an in vitro study using
HUVEC (Izuta et al., 2009) and CAPE in an in vitro study using human
breast adenocarcinoma (MDA-MB-231) cells (Wu et al., 2011)). An
additional report by Daleprane and Abdalla (2013) showed that the
anti-angiogenic effect of the Brazilian red propolis corresponded with a
decrease in hypoxia inducible factor 1-alpha (HIF-1α) protein expression
in endothelial cells under hypoxic conditions. Moreover, an increase in
the von Hippel–Lindau tumour suppressor protein level (pVHL), and an
attenuation of VEGF gene expression was observed, which diminished
the migration and sprouting of endothelial cells (Daleprane and Abdalla,
2013). Interestingly, Xuan et al. (2011) discovered that the ethanolic
extract of Brazilian brown propolis could modulate both proliferation
and apoptosis of endothelial cells in a dose-dependent manner. They
reported that a lower concentration of the ethanolic extract of propolis
(12.5 μg/ml) could induce proliferation by decreasing the expression of
p53 and ROS levels. Alternatively, high concentrations of the ethanolic
extract of propolis (25 and 50 μg/ml) led to apoptosis by increasing the
level of p53 and ROS at 24 hours while reducing the mitochondrial
membrane potential level at all times.
As a potent anti-angiogenic compound, propolis may potentially have
remarkable effects towards cancer cells, as both cancer and angiogenesis
are intertwined with each other. However, the mechanism of action of
propolis in eliminating cancer cells may not always work through the
angiogenesis pathway. Aside from affecting angiogenesis, some studies
have found that various propolis samples and pure compounds can block
particular oncogene signalling pathways, increase apoptosis, decrease
the cancer stem cell population and modulate the tumour microenvi-
ronment (Sawicka et al., 2012; Chan et al., 2013). Furthermore, Alizadeh
et al. (2015) investigated the chemoprotective effects of the ethanolic
extract of Iranian poplar-type propolis on N-methyl-N-nitro-N-ni-
trosoguanidine-(MNNG-)-induced-gastric cancer in rats, with a signiﬁ-
cant reduction in nuclear/cytoplasmic ratio, epithelial stratiﬁcation,
structural abnormality and Beta-catenin and Bcl-2 protein expressions.
Despite all of these therapeutic potentials, propolis from around the
world are still poorly characterized. This phenomenon is also one of the
main reasons why propolis has not been included in mainstream drugs
yet, in spite of its increasing popularity and scientiﬁc ﬁndings (Bankova,
2005). It is uncertain whether the bioactivities that have been found in
some propolis samples would be found in other samples as well. There-
fore, preliminary research on the sample of interest to determine its
unique biological activities is warranted before advancing to its2utilization. In this study, two Indonesian propolis samples from Sulawesi
Island, D01 and D02, were tested on several cell lines for their potential
as an anti-angiogenic drug in tumour microenvironment. Two cell lines,
human umbilical vein endothelial cells (HUVECs) and pericytes, were
used for this objective, while MDA-MB-231 cells was used as a compar-
ison to see how these samples affect cancer cells as a hint of their further
applicability in treating tumour angiogenesis. HUVECs and pericytes are
being used as a model of the microvascular environment, whereas the
MDA-MB-231 cell line is a common model in cancer research.
2. Material and method
2.1. Materials
Indonesian propolis samples (D01 & D02) were a gift from Dr.
Muhamad Sahlan from the Department of Chemical Engineering, Uni-
versitas Indonesia. D01 and D02 are classiﬁed as paciﬁc-type brown
propolis from Trigona sp. and were harvested in North Luwu Regency,
South Sulawesi Province, Indonesia. D01 was harvested from the inner
side of the hive, while D02 was from the outer side of the same hive.
Human umbilical vein endothelial cells (HUVECs) and placenta-derived
pericytes were from Promocell, Heidelberg, Germany. The MDA-MB-
231 human breast cancer cell line was a gift from Fahy Gurteen UK
Ltd, Cambridge, United Kingdom. Caffeic acid phenethyl ester (CAPE)
was from Abcam, Cambridge, UK, and pinocembrin was from Sigma-
Aldrich, HaverHill, UK. Endothelial basal medium 2 and supplement
kit were from Promocell, Heidelberg, Germany. Pericyte growth medium
and supplement kit were from Promocell, Heidelberg, Germany. Dul-
becco's Modiﬁed Eagle Medium (DMEM), foetal bovine serum (FBS),
antibiotic-antimycotic, trypsin/EDTA solution, trypan blue solution (0.4
%), human recombinant VEGF and 13 mm Thermanox cell culture cov-
erslips were from Gibco Life Science, Paisley, UK. Phosphate Buffered
Saline (PBS) was from Oxoid Ltd, Basingstoke, UK. Dimethyl Sulfoxide
(DMSO), cobalt chloride (CoCl2), and Taxol were from Sigma-Aldrich,
Gillingham, UK. The CCK-8 solution was from Dojindo Molecular Tech-
nologies, Inc., Japan. Fibroblast growth factor was from Prospec, Reho-
vot, Israel.
2.2. Preparation of propolis
Both samples were extracted at Strathclyde Institute of Pharmacy and
Biomedical Sciences, University of Strathclyde, Glasgow. The extraction
was performed in an ethanolic-based extraction system. Brieﬂy, 15 grams
of raw propolis was macerated in 1 litre of absolute ethanol with soni-
cation in 37 C for an hour. The solution was then ﬁltered and the process
was repeated two more times to achieve an increased yield in the ﬁltrate.
Following the extraction process, the ﬁltrate was then dried and ca 10
grams of dried ﬁltrate was obtained. To prepare the extracts of the
samples from Ghana, Nigeria, Saudi Arabia, and New Zealand 50 mg of
each sample was extracted with 5 ml of ethanol by sonication for 1 hour
at 37 C. The extraction solution was blow to dryness, weighed and then
made up in methanol to give a 1 mg/ml solution.
2.3. LC-MS proﬁling of the propolis samples
Propolis extracts were dissolved in methanol (1 mg/ml) and 10μl of
the solutions were injected into the LC-MS. High resolution mass spectra
were obtained using an linear trap quadropole orbitrap mass spectrom-
etry (LTQ Orbitrap MS) (Thermo Fisher, Hemel Hempstead UK) in
negative ion mode with a needle voltage of -4.0 kV, and a sheath gas ﬂow
as well as an auxiliary gas ﬂow of 50 and 10 arbitrary units, respectively.
Separation was carried out on an ACE-C18 column (150  3 mm, 3 μm)
(HiChrom, Reading, UK) with 0.1%v/v formic acid in water as mobile
phase A and 0.1%v/v formic acid in acetonitrile (ACN) as mobile phase B
at a ﬂow rate of 300 μl/min. The gradient programme was as follows:
0 min (25% B), 30 min (100% B), 35 min (100% B), 36 min 25% B, 41
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(Pluskal et al., 2010) and then searched against a database compiled from
the Dictionary of Natural Products (Buckingham, 1993). Putative iden-
tities were assigned according to mass matching to elemental composi-
tion to within 3 ppm. The extracted data was analysed using Orthogonal
Partial Least Squares Discriminant Analysis (OPLSDA) using Simca P 14.1
(Umetrics, Sweden).
2.4. Cell culture
HUVECs were cultured in endothelial cell basal medium-2, supple-
mented with 1% antibiotic-antimycotic solution (ANTI-ANTI) and a
supplement kit, according to manufacturer instructions. This supple-
mented medium is henceforth referred to as endothelial cell growth
medium (EGM-2). For general usage, HUVECs were incubated at 37 C
with humidiﬁed air containing 5% CO2. In this study, assays to HUVECs
were performed using the basal medium to optimally monitor the
comparative effect of additional growth factors. Cells were used in pas-
sages 2 to 8 for this study.
Pericytes were cultured in a similar way as HUVECs but using pericyte
growth medium (PGM). This medium was supplemented with 1% ANTI-
ANTI solution and a supplement mix. To perform downstream assays, the
complete medium is used instead of the titrated medium due to the
absence of basal medium in Promocell pericyte growth medium product.
Passage 2 to 8 were used in this study.
MDA-MB-231 cells were cultured in Dulbecco's Modiﬁed Eagle Me-
dium (DMEM) supplemented with 10% FBS and 1% ANTI-ANTI.
Generally, MDA-MB-231 cells were cultured in a similar way as
HUVECs and pericytes. Complete medium was used for downstream as-
says. This was to ensure the growth environment resembles realistic
conditions where cancer cells can fully proliferate. Passage 3 to 9 were
used in this study.
2.5. Cell viability assay
To measure cell viability following the propolis treatment, a cell
counting kit-8 (CCK-8) solution was used. CCK-8 is a sensitive colori-
metric assay for determining the number of viable cells in cell prolifer-
ation and cytotoxicity assays. The detection sensitivity of CCK-8 is
increased than other tetrazolium salts, such as MTT, XTT, MTS or WST-1.
Although the calibration curve for certain cell lines did not exist at the
time of the experiment, using CCK-8 is still useful to provide us an ac-
curate proxy of cell viability following the drug treatment compared to
the vehicle controls in the experiments.
To perform the cell viability assay, HUVECs, pericytes, and MDA-MB-
231 cells were trypsinised, counted and seeded onto 96 well plates at a
density of 2,500 cells per well for HUVECs and pericytes, and 10,000 cells
per well for MDA-MB-231 cells. The plates were then incubated for 24
hours to allow the cells to begin proliferating. The drug testing step was
performed by changing the medium using an appropriate medium with
the addition of different concentrations of DMSO-diluted drug samples.
The dilution of drug samples into the medium was in the ratio of 1:1000
to minimise possible DMSO toxicity to the cells, and the total volume of
medium-drug solution in one well is 100 μl. For the experimental con-
trols, 0.1% DMSO was used as a vehicle control, while Taxol was used as
a positive control. We use Taxol as a positive control because from pre-
liminary investigations (i.e., literature study, preliminary experiments),
we observed that the drug samples (propolis) may possess anti-
angiogenic properties. Besides, we also used both CAPE and pinocem-
brin as drug samples—two of the most common propolis pure com-
pounds—to show a comparability between the propolis samples and the
pure compounds. The cells were incubated for 48 hours and following
incubation 10 μl of CCK-8 solution was added to each well, and plates
were further incubated for 2 hours in darkness at 37 C. Lastly, the
absorbance at 450 nm was then measured with a 96-well plates reader.3To avoid interference from background colorimetric effects, plates of the
blank sample containing just medium were also tested. The blank control
absorbance values were then subtracted from the treatment values to
calculate the corrected absorbance values of wells.
In addition to performing the standard cell viability assay, we also
modiﬁed the experiment in order to provide evidence regarding how the
drug samples/propolis interact on selected cells. The modiﬁcation
included the addition of growth factors in HUVEC experiments and the
addition of CoCl2 to generate hypoxia conditions in pericyte experiments.
For experiments that involved growth factor effects in HUVECs, each well
was supplemented with 20 ng/ml of VEGF and 50 ng/ml of ﬁbroblast
growth factor (FGF) when testing the drug samples. For the hypoxia
experiment of pericyte, CoCl2 was added to each well 2 hours after
changing the medium prior to 24 hours incubation.
2.6. Wound healing/migration assay
HUVECs, pericytes, and MDA-MB-231 cells were trypsinised, counted
and seeded onto 13mm diameter Thermanox coverslips placed in 24-well
plates at a density of 20,000 cells per well for HUVEC and pericytes, and
40,000 cells per well for MDA-MB-231 cells. The plates were incubated
until they became conﬂuent (approximately 5 days). Once conﬂuent,
each well was treated with 10 μg/ml of mitomycin-C two hours prior to
the wounding process in order to stop cell proliferation. The coverslips
were then wounded using a speciﬁcally designed mechanical wounder,
which produces 11 lesions with 400 μm distance between the lesions.
Next, they were rinsed with PBS three times before being placed into a
24-well plate containing fresh corresponding medium and appropriate
concentration of the drug samples. The total volume of medium and drug
in one well is 400 μl. To establish the time zero control, some wells were
ﬁxed immediately after wounding using 500 μl methanol for 5 minutes.
Then, the plates were further incubated for 8 hours before ﬁnally being
ﬁxed. Following ﬁxation, a photomicrograph of each coverslip was taken
and the denuded area was analysed using ImageJ software to quantify the
ability of the cells to migrate over 8 hours.
2.7. Statistical analysis
For statistical analysis, Microsoft Excel and Graphpad Prism 5 soft-
ware were used. Ordinary one-way analysis of variance (ANOVA) with a
Tukey's or Dunnett's multiple comparisons test was performed to
compare the mean of each treatment group with the mean of the control
(vehicle and positive control). An unpaired two-tailed t-test was per-
formed to compare any signiﬁcant difference between the treatment.
Data are always reported as mean  SD. Signiﬁcance is reported as a *
which represents stimulatory effect (* for P < 0.05, ** for P < 0.01, and
*** for P < 0.001) and # which represents inhibitory or cytotoxic effect
(# for P< 0.05, ## for P< 0.01, and ### for P< 0.001). A * sign is also
used to indicate a level of signiﬁcance in the t-test experiments (* for P <
0.05, ** for P < 0.01, and *** for P < 0.001).
3. Results
3.1. LC-MS proﬁles of D01 and D02
Fig. 1 shows a comparison of the two Indonesian samples with sam-
ples of propolis from Nigeria, Ghana, New Zealand and Saudi Arabia
using the 950 most abundant components in the samples to construct an
OPLSDA model. It was putatively found that the Indonesian samples are
similar to each other but very different from the other samples which
contain abundant ﬂavonoids. Although the Indonesian samples were
similar to each other in comparison to the Nigerian, Saudi, Ghanaian and
New Zealand samples, they differ from each other and Tables 1 and 2
show the ten tentatively identiﬁed components with putative identiﬁ-
cations and elemental compositions in each sample. It is observed that
Fig. 1. Separation for six propolis samples using OPLSDA based on the 950 most abundant compounds in the samples.
Table 1
The 10 tentatively identiﬁed components in sample D01 in negative ion mode. Putatively identiﬁed according to accurate mass <3 ppm from assigned elemental
composition.
m/z Rt min Elemental Comp. Putative identiﬁcation
399.2542 23.6 C25H36O4 Actinopyrone A
447.2755 22.3 C26H40O6 Amphidinolide X
445.2599 16.7 C26H38O6 Acetoxy-acetoxymethyl-acetoxymethylene-dimethyhexadecatetraene
445.26 16.1 C26H38O6 Acetoxy-acetoxymethyl-acetoxymethylene-dimethylhexadecatetraene
385.2389 21.7 C24H34O4 Abietatrienediol Di-Acetate
445.2597 17 C26H38O6 Acetoxyacetoxymethylacetoxymethylenedimethylhexadecatetraene
451.213 17.5 C27H32O6 Arisugacin E; 3-Ketone
447.2754 20.8 C26H40O6 Amphidinolide X
449.2549 14.3 C25H38O7 Daucanetriol Trimethoxybenzoyl
433.2598 24.5 C25H38O6 Abeo-dihydroxy-eremophilenolide 1-O-(2-Methylbutanoyl), 9-O-(3-methylbutanoyl)
Table 2
The 10 tentatively identiﬁed components in sample D02 in negative ion mode.
m/z Rt
min
Elemental
Comp.
Putative identiﬁcation
351.2178 16.3 C20H32O5 11(15->1)-Abeo-4(20),11-taxadiene-
5,9,10,13,15-pentol
315.0512 10.6 C16H12O7 2-Acetyl-1,3,6,8-tetrahydroxyanthraquinone;
10R-Alcohol
363.1817 8.9 C20H28O6 19(4->3)-Abeo-4,5-epoxy-1,6,7,14-
vouacapanetetrol
381.1922 7.4 C20H30O7 11(15->1)-Abeo-5,20:13,15-diepoxy-11-
taxene-2,4,7,9,10-pentol
349.202 9.9 C20H30O5 7(8->9)-Abeo-1,9-dihydroxy-11(13)-
eremophilen-8,12-olide; (1?,7?,9?)-form, 1-O-
(3-Methylbutanoyl)
303.1966 19.4 C19H28O3 Acalycixeniolide K
317.2121 22.1 C20H30O3 6,8(14),15-Abietatriene-3,11,17-triol
319.1916 14.4 C19H28O4 7(8->9)-Abeo-9-hydroxy-11(13)-
eremophilen-8,12-olide; (7?,9?,10?)-form, 2-
Methylpropanoyl
333.2072 17.5 C20H30O4 20(10->9)-Abeo-6,16-dihydroxy-19,10-
kauranolide
289.1809 16.4 C18H26O3 2-Alkyl-5-hydroxy-4H-1-benzopyran-4-ones;
5-Hydroxy-2-nonyl-4H-1-benzopyran-4-one,
2?,3-Dihydro
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4these identiﬁed chemicals are the most abundant components of each
sample, but further conﬁrmation is needed to claim such ﬁndings.3.2. Effect of the samples on cell viability
In Fig. 2, dose-response curves of the effects of different concentra-
tions of the samples towards the viability of the three cell lines are
shown. Between the two crude extracts, D01 exhibited a much stronger
inhibitory or cytotoxic effect on HUVECs, pericytes and MDA-MB-231
when compared to D02. Furthermore, it can be seen from Fig. 2 that
D02 could not reach a maximum inhibition at the highest soluble con-
centration of this study (D02 is not soluble in 1000 μg/ml concentration),
resulting in non-converged D02 curves on the graph plots of the three
cells.
For the experiments on HUVECs, although D01 did not demonstrate
an inhibitory or cytotoxic effect until 10 μg/ml, the graph shows a steep
decline after the respective value with a hill coefﬁcient of about 4
(Fig. 2a). However, the inhibitory or cytotoxic potential of D01 to peri-
cytes and its Hill coefﬁcient are drastically reduced compared to the
value in the HUVEC experiment (Fig. 2b). In terms of the IC50 value, the
biological activity of CAPE towards both cells is actually more potent
than D01 (Table 3a-b. The graphs of CAPE and pinocembrin are not
shown). However, the inhibitory or cytotoxic effect of D01 may or may
not be derived from the interaction of its pure compounds. If it actually
(a)
(b)
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Fig. 2. Cell Viability of (a). HUVEC (b). pericytes and (c). MDA-MB 231 cells when Treated with Propolis Extracts. The cells were treated with various concentrations
of D01 and D02. After 48 hours of incubation, 10μl/well of the CCK-8 solution was added and the absorbance at 450nM was measured. Data are expressed as
absorbance values with normalization to the basal values of cells with DMSO as the control, which show means SD and represent biological replicates. Taxol was
used as a positive control of anti-angiogenesis to be compared with the samples. The best ﬁt curve was produced by analyzing the predicted residual error sum of
squares (PRESS). Bullets signify the actual average experimental data. The experiment was repeated three times with ﬁve technical replicates in each experiment. Data
of D02 did not produce a converged curve on HUVECs' and pericytes' curves. Furthermore, D02 barely exhibited an inhibitory or cytotoxic effect on MDA-MB-231 cells
(the plot is not depicted for efﬁciency).
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Table 3
IC50 of D01 and pure compounds on (a). HUVECs (b). pericytes and (c). MDA-MB-
231 cells (n ¼ 3). The graphs of CAPE and pinocembrin are not shown.
Sample IC50. 1 IC50. 2 IC50. 3 Average  Standard
Deviation
(a)
D01 (μg/ml) 15.7 13.6 14.7 14.7  1.01
CAPE (μg/ml) 0.68 0.92 0.73 0.78  0.13
Pinocembrin (μg/
ml)
18.1 13.7 20.7 17.5  3.55
(b)
D01 (μg/ml) 67.2 58.8 55.2 60.4  6.14
CAPE (μg/ml) 4.42 4.14 3.19 3.91  0.64
Pinocembrin (μg/
ml)
41.8 38.5 29.6 36.6  6.33
(c)
D01 (μg/ml) 53.4 53.1 41.7 49.4  6.69
CAPE (μg/ml) 35.9 42.1 43.8 40.6  4.17
Pinocembrin (μg/
ml)
35.9 39.8 45 40.2  4.52
M. Iqbal et al. Heliyon 5 (2019) e01978came from just one or two single compound(s), the biological activity of
that unknown compound(s) may be higher than CAPE, provided the fact
that one single propolis pure compound may constitute a tiny percentage
of the total volume. The comparison between D01's and the pure com-
pounds' results towards the three cell lines are shown in Table 3.
A unique feature of the dose-response curves of D01 on HUVECs and
pericytes is their tendency to be biphasic. While it has been proven that
D01 exhibited a strong inhibitory or cytotoxic activity towards both cells,
the graphs do not decline until they increase ﬁrst, indicating a slight
proliferative effect of D01 in the lower concentrations. In contrast, the
results of D01 on MDA-MB-231 do not produce a biphasic curve even
though they show a relatively similar pattern to what happened to
HUVECs and pericytes (Fig. 2c). These results provide a further proxy
about the modulatory effect of propolis on different cells, which needs to
be further investigated.Fig. 3. Effect of The Propolis Samples on The Growth Factors-Enhanced HUVECs. H
various concentration of (a) D01 and (b) D02. After 48 hours of incubation, 10μl/we
These data are compared with the absorbance of HUVECs treated without growth fa
graphic trends with HUVEC data in Fig. 2. Data are expressed as absorbance values
represent biological replicates. The experiment was repeated two times with ﬁve tec
63.3. The propolis samples and pure compounds have no effect on VEGF
and FGF activities
To further investigate whether the samples may have interactions
with the growth factors of endothelial cells, additional cell viability as-
says were performed by adding 20 ng/ml of VEGF and 50 ng/ml of bFGF
to the HUVEC experiment. The vehicle control in this experiment was the
growth factors-enhanced DMSO-treated cells. The results of this experi-
ment were compared to another group which the cells were not enhanced
with additional growth factors. By comparing these results, a hypothesis
about a possible interaction between the propolis samples and the
endothelial cell growth factors may be generated. If the inhibition per-
centage of propolis on the growth factors-enhanced HUVECs was
increased when compared to the non-growth factors-enhanced HUVECs,
there may be a possible nexus between the propolis samples suppressive
activities and the growth factors activities on HUVECs. Fig. 3 illustrates
the cell viability results of both conditions and points to them having a
similar trend. However, the inhibition percentages in both conditions do
not produce a signiﬁcantly statistical difference, thus negating the hy-
pothesis (calculation not shown).
3.4. Effect of the samples on migratory activity of the cells
Although D01 and D02 performed remarkably different in the cell
viability assays, their results in the wound healing assays are barely
distinctive and show a similar downward trend at almost the same po-
tency. Between 0.01 – 10 μg/ml, both D01 and D02 were able to inhibit
the migratory activity of HUVECs in the half capacity of Taxol 1 nm
(Fig. 4a). On the other hand, both extracts suppressed the cancer cells in a
comparable level to Taxol 1 nm for all tested concentrations (Fig. 4c). Of
important notes, D01 at 1 and 10 μg/ml were even stronger than taxol 1
nm in inhibiting MDA-MB-231 cell migration (35% inhibition by D01 at
1 and 10 μg/ml versus 25% inhibition by taxol 1 nm as shown in Fig. 4c).
However, none of these results to both cells produces a dose-response
curve, as most of them ﬂuctuate between certain values. Aside from
those results, they did not induce a signiﬁcant inhibition to pericyte
migration (Fig. 4b).UVECs were treated with VEGF (20 ng/ml) and bFGF (50 ng/ml), and also the
ll of CCK-8 solution was added and the absorbances at 450nM were measured.
ctors but with the same concentration of propolis samples, which have similar
with normalization to the basal values of cells with DMSO as the control and
hnical replicates in each experiment.
Fig. 4. Wound Healing/Cell Migration Rate of (a). HUVECs (b). pericytes and (c). MDA-MB-231 cells when Exposed to Propolis Samples for 8 Hours. In 24 well-plates,
the cells were grown until conﬂuent before wounding by a mechanical wounder to produce 11 lesions on the cell monolayers. 10 μg/ml ﬁnal concentration of
mitomycin-C was added 2 hours prior to wounding. Next, the cells were treated with D01 and D02 at the concentrations where they do not induce cytotoxicity. DMSO
0.1% was used as the vehicle control. After 8 hours, all wells were ﬁxed using methanol and the resulted images were analyzed by ImageJ. Data are expressed as
average % recovery values compared to the time-zero control with no normalization and represent biological replicates. An ordinary one-way ANOVA was performed
with a Dunnett's multiple comparisons test where the mean of each group was compared with the mean of the vehicle control group for each drug separately. Sig-
niﬁcance is reported as a * which represents a recovery effect (* for P < 0.05, ** for P < 0.01, and *** for P < 0.001) and a # which represents an inhibitory effect (#
for P < 0.05, ## for P < 0.01, and ### for P < 0.001). The experiment was repeated two times with four technical replicates in each experiment. Figure (d) is the
example of photomicrograph of wound healing experiment using D01 on MDA-MB-231 cells.
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M. Iqbal et al. Heliyon 5 (2019) e019783.5. D02 retained the cell viability of CoCl2-treated pericytes
Aside from investigating cytotoxicity and migratory proﬁles resulted
on the three cell lines after treated with the propolis samples, the effect of
the samples in protecting pericytes against hypoxia is also of interest
since hypoxia induced-pericyte dropout is a common phenomenon in
tumour angiogenesis (Xian et al., 2006; Raza et al., 2010). CoCl2 addition
was performed to mimic hypoxic condition in the cell culture Wu and
Yotnda (2011). The results of this experiment demonstrate that D02
potentially counteracted the CoCl2-induced pericyte loss by delivering a
consistent protection in a dose-dependent manner as depicted by Fig. 5. If
the assumption of CoCl2-induced hypoxia in this experiment was correct,
this result may lead to a hypothesis that D02 can ameliorate
angiogenesis-related hypoxic microenvironment in tumours, even
though its direct inhibitory or cytotoxic activity on HUVECs and pericytes
was not strong.Fig. 5. Effect of Propolis Samples on CoCl2-induced Pericyte Loss. Pericytes were trea
except the control wells, were further added with CoCl2, giving the ﬁnal concentration
and the absorbances of 450nM was measured. Data are expressed as absorbance value
show means SD and represent biological replicates. An ordinary one-way ANOVA wa
was compared to the vehicle control group (DMSO), and the other treatments were
treatment against pericyte dropout, either stimulatory/recovery (*) or inhibitory/cyto
for P < 0.05, ** for P < 0.01, and *** for P < 0.001) and # which represents an in
0.001). While in (c), the protection percentage of propolis-samples-treated pericytes
obtained by calculating the percentage of change between the data of each sample to t
repeated two times with ﬁve technical replicates in each experiment.
84. Discussion
4.1. Analysis of propolis extracts
The most abundant tentatively identiﬁed compounds in Indonesian
sample D01 from LC-MS analysis seem to be unusual in that they do not
obviously fall into a class such as ﬂavonoids or terpenoids. Two of the
most abundant compounds have elemental compositions matching acti-
nopyrones which are terpenoid derivatives and antibiotic compounds
isolated from Streptomyces pactum (Yano et al., 1986). The putative
presence of these antibiotic compounds justiﬁes the role of D01 as an
antiseptic inside the hive of its former colony. Although, it is not possible
to be deﬁnitive of identity on the basis of elemental composition, but it
would seem the compounds in D01 are possibly modiﬁed terpenoids. On
the other hand, D02 has abundant compounds which ﬁt better with
various classes of compound and putatively include four related diter-
penes with differing degrees of oxygenation and some sesquiterpenes.
These results conform to the common characteristic of Indonesian
propolis which usually contains terpenes and terpenoids (Trusheva et al.,
2011). The plant source of the terpenes of these samples is possibly
Mangifera indicawhich is common in the area of harvesting. However, theted with various concentrations of (a) D01 and (b) D02. After 2 hours, each well,
of 250μM. After 24 hours of incubation, 10μl/well of CCK-8 solution was added
s with normalization to the basal values of cells with DMSO as the control, which
s performed with a Tukey's multiple comparisons test. The DMSO þ CoCl2 group
compared to the DMSO þ CoCl2 group in order to assess the effect of propolis
toxic (#). Signiﬁcance is reported as a * which represents a stimulatory effect (*
hibitory or cytotoxic effect (# for P < 0.05, ## for P < 0.01, and ### for P <
after experiencing a CoCl2-induced decline (pericyte loss) is depicted. Data were
he control data (samples which were treated by CoCl2 only). The experiment was
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phytochemical exploration will be conducted in the future.4.2. Indonesian propolis is potentially anti-angiogenic in vitro
Recent literature has demonstrated that propolis has anti-angiogenic
activity both in vivo and in vitro. Many papers already reported its possible
mechanisms in suppressing angiogenesis and tumour-related angiogen-
esis. One of the possible pathways is by inducing apoptosis in vascular
cells and upregulating the level of some apoptosis-related markers such
as p53, ROS, and caspase-3 (Xuan et al., 2011; Kunimasa et al., 2011). An
Additional possible mechanism is suppression of VEGF gene expression,
which is one of the principal regulators of angiogenesis, as reported by
Daleprane and Abdalla (2013), and Izuta et al. (2009).
This study provides a hypothesis that Indonesian propolis from
Sulawesi Island may have an anti-angiogenic activity. D01 was quite
effective in suppressing HUVEC viability at 10 μg/ml and above with a
relatively low IC50 value and a high Hill coefﬁcient (approximately 4), in
a dose-dependent manner. Furthermore, the Hill coefﬁcient of D01 is
much larger than of CAPE and pinocembrin (0.75 and 0.8, respective-
ly—the graphics are not shown) although the IC50 of D01 is much higher
than CAPE's. From a statistical point of view, the steeper the curve means
the more potent the drug at small increases in concentration. In general,
this number may indicate a positive cooperativity among ligand-binding
sites between the cells and D01, leading to a higher expected therapeutic
effectiveness compared to drugs with hill coefﬁcient 1 or less i.e. no
cooperativity between ligand-binding site. This hypothesis may have a
relevancy to a natural product like propolis whose diverse compounds
allow interactions and modulations of its activities towards cells. From
the result of compound analysis, modiﬁed terpenes are presumably the
major contributors of this bioactivity. In fact, there are some reports
about antiangiogenic activities of terpenes and terpenoids through
several pathways (Kim et al., 2000; Sogno et al., 2009).
In Fig. 6, the morphological observations of HUVECs upon exposure
to different concentrations of D01 corroborate the cell viability assay
results. The lower results of the cell viability assay, which relate to the
higher concentrations of samples, were reﬂected by more rounded cells
with compromised cell density. In contrast, control cells demonstrated a
dense normal cell population with very few rounded cells.
An increased rounded cell population in a cell culture may suggest
two common phenomena in the cells: apoptosis and mitotic arrest. BothFig. 6. Photomicrographs of HUVECs after the incubation with D01 for 48 hours. HU
ml, (c) 1 μg/ml, (d) 0.1 μg/ml, (e) DMSO, and (f) 8nM Taxol. The images were taken
Phase Contrast ELWD 0.3 microscope at 80X magniﬁcation.
9phenomena induce a formation of rounded cells in the late stage of their
mechanism. The presence of rounded cells in apoptosis is due to the
breakdown of proteinaceous cytoskeleton by caspases (Bohm, 2003).
Alternatively, the rounded cell phenomenon in a mitotic arrest represents
cells in metaphase, which cannot advance to the next step of mitosis.
Rounded cells normally occur in mitosis when cells down-regulate focal
adhesions and increase their cortical tension and intracellular pressure
(Stewart et al., 2011). Furthermore, a mitotic cell rounding is also
involved in tissue organization, development, and homeostasis of
dividing cells (Luxenburg et al., 2011; Kondo and hayashi, 2013).
Between those two phenomena, apoptosis is a more common expla-
nation behind propolis’ suppressing action to vascular cells. In this study,
it is also conﬁrmed from the results of the growth factors-enhanced
experiment on HUVECs. The relatively similar results between the two
groups (with and without additional growth factors) compared to their
respective vehicle control indicates an absent of cell cycle arrest, which
signiﬁes the insigniﬁcant effect of D01 towards microtubule dynamics.
On the contrary, Taxol presented a signiﬁcant difference between the
two groups, where the suppression of viability to the group with addi-
tional growth factors was stronger than the group without additional
growth factors, conﬁrming their function as an anti-mitotic drug. This
hypothesis is substantiated by the results of the wound healing assay.
Even though the results of the wound healing experiment of D01 are
statistically signiﬁcant in suppressing the cell migration of HUVECs—-
which strongly relates to microtubule dynamics—, they did not show a
dose-response relationship. The absence of dose-response relationship in
a migration assay demonstrates an indication of the indirect effect of the
samples to microtubule dynamics, which needs to be further investi-
gated. As a result of this hypothesis, the possibility of direct apoptosis as
the main mechanism of D01 to suppress the HUVECs viability is now
more plausible to prove.
In addition to the rounded cells, the indication of apoptosis in the
present study can also be observed from the apoptotic bodies on the
HUVECs’ photomicrographs (Fig. 6) especially at the higher concentra-
tions of D01. These results may further strengthen the occurrence of
apoptosis in the HUVECs following the treatment by D01.
Furthermore, provided the fact that D01 potentially suppress HUVEC
viability, the analysis of its activity to pericytes was interesting. Pericytes
are another major player of angiogenesis, which promote vessel stability
by covering endothelial cells and producing chemical signals to maintain
the attachment of both cells (Hall, 2006). The role of pericytes in normalVECs were treated with various concentrations of D01: (a) 100 μg/ml, (b) 10 μg/
after 48 hours of incubation and before addition of CCK-8 solution using Nikon
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targeting only VEGFR-2 for inhibiting angiogenesis is not effective to
degrade tumour cells because the endothelial cells are protected and
stabilized by pericyte coverage. Interestingly, VEGF inhibition may also
increase pericyte recruitment in tumour vessels (Benjamin et al., 1999),
which may lead to pericyte-mediated resistance to VEGF-related anti--
angiogenic therapies (Raza et al., 2010). Thus, achieving both endothe-
lial cell and pericyte degradation in tumour vasculatures is important to
simultaneously prevent their reformation and survival signals (Bergers
et al., 2003).
The ﬁndings in this work suggest that D01 has a potential inhibitory
or cytotoxic effect to pericytes, although not as strong as to HUVECs,
which may support the evidence of its therapeutic effects on tumour
angiogenesis. From the respective ﬁgures (Fig. 7), it can be presumed that
the mechanism of D01 in suppressing pericyte viability is tantamount to
the mechanism on HUVECs. The presence of rounded cells with sus-
pended cell extension and low cell density was common, especially at the
higher concentrations of the samples. Based on the previous analysis,
direct apoptosis may also be the main mechanism of D01 to reduce
pericyte viability.4.3. Protective activity of propolis on CoCl2-induced pericyte loss
As an inherent aspect of inﬂammation, hypoxia plays an important
role in the pathogenesis of many inﬂammation-related diseases including
cancer. In the tumour microenvironment, hypoxia initiates tumour
angiogenesis, which provides cancer cells with sufﬁcient oxygen and
nutrients. In addition, hypoxia affects destabilization of the vessels by
inducing pericyte loss, which makes the endothelial cell sprouting
possible. Unlike endothelial cells, the role of pericytes in tumour angio-
genesis remains controversial. Although pericyte recruitment is
perceived to promote cancer cell survival by stabilizing tumour vascu-
lature as explained in the previous section, there are actually some
contradictions whether pericyte recruitment in tumour vessels amelio-
rate or worsen the clinical conditions. Alternatively, instead of stabilizing
vessels to support cancer cells, pericyte recruitment is important to
restrict further vessel sprouting by—again—stabilizing the vessels. In
addition, tumours with lower pericyte density are usually distinguished
by a compact vasculature with active endothelial cell proliferation
(Eberhard et al., 2000). Stabilization of the vessels may also limit tumour
cell metastasis by reducing the leakiness of intratumoural blood vesselsFig. 7. Photomicrographs of pericytes after the incubation with D01 for 48 hours. Pe
μg/ml, (c) 10 μg/ml, (d) 1 μg/ml, (e) DMSO, and (f) 8nM Taxol. The images were take
Phase Contrast ELWD 0.3 microscope at 80X magniﬁcation.
10(Xian et al., 2006; Raza et al., 2010).
From this perspective, maintaining pericyte attachment to the vessels
and preventing any pericyte loss is paramount to avoid unwanted
angiogenesis in the tumour microenvironment. Therefore, protection of
pericytes from hypoxia-induced loss can be one of the proposed mecha-
nisms to inhibit tumour angiogenesis. In these experiments, CoCl2 was
used to mimic hypoxic condition by inducing and stabilizing HIF-1/3α
(Wu and Yotnda, 2011). The administration of CoCl2 to the pericytes in
these experiments led to a major decline of their viability, which may
relate to the “pericyte dropout” phenomenon in several angiogenesis
diseases e.g. cancer, diabetic retinopathy, atherosclerosis and even in
some cases of Alzheimer's disease (Data is represented in Fig. 5; The
CoCl2-treated cells show a decline compared to the vehicle control).
D01 and D02 showed positive results by increasing the cell viability of
CoCl2-treated pericytes when compared to the control. Interestingly,
while D01 just restored the cell viability in certain concentrations,
Indonesian propolis sample D02 was able to protect pericytes against
CoCl2-induced loss in a dose-dependent manner. Thus, while D02 seemed
to be ineffective to block HUVEC and pericyte proliferation, it may
possess another bioactivity, which can synergise with anti-angiogenic
drugs by protecting pericytes from hypoxia-induced loss.
While the exact mechanism of D02 in protecting pericytes against
hypoxia-induced damage remain unknown, it may include a destabili-
zation of HIF-1α (Daleprane and Abdalla, 2013) and a reduction of
reactive oxygen species (ROS) by the abundant anti-oxidant compounds
in propolis (Xuan et al., 2011). However, the chelation of CoCl2 by
propolis samples may also become a robust alternative argument in this
regard. Hence, a conﬁrmation of their mechanism of action is still a top
priority before conﬁrming such a claim.4.4. Indonesian propolis samples induce potential modulatory activities on
different cell lines
It is interesting to notice that D01 induced a different pattern of ac-
tivities on HUVECs, pericytes, and MDA-MB-231 compared to the pure
compounds: CAPE and pinocembrin. One aspect worth highlighting is
D01's weaker cytotoxic activity on pericytes compared to MDA-MB-231
cells as shown in Table 3b-c (IC50 62.35 μg/ml vs 48.23 μg/ml, respec-
tively). In the case of CAPE and pinocembrin, their order of cytotoxic
strength to these three cell lines is HUVECs > pericytes >MDA-MB-231.
However, the order for D01 is HUVECs > MDA-MB-231 > pericytes. Inricytes were treated with various concentrations of D01: (a) 1000 μg/ml, (b) 100
n after 48 hours of incubation and before addition of CCK-8 solution using Nikon
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pinocembrin, where it elicits a moderate elimination to HUVECs, a
weaker activity to pericytes, but a considerably similar potency to
destroy MDA-MB-231 cells (Table 3). This ﬁnding may correspond to the
question of how to deal with pericytes in tumour vasculature as discussed
in the previous section. In the case where pericyte population needs to be
maintained in order to prevent endothelial cell sprouting, administration
of D01 may aid by suppressing HUVECs population and moderately
eliminating cancer cells, at a level where it is not severely cytotoxic to
pericytes. For example, administration of 32 μg/ml D01 extract (the
median of IC50 to HUVECs and MDA-MB-231) may suppress 97%
HUVECs, 33% MDA-MB-231 and 28% pericytes. The potency of D01 in
inhibiting the cell migration on both HUVECs and MDA-MB-231 cells,
but not on pericytes, also supports this hypothesis.
Unlike D01, D02 appeared to be unsuitable as a cytotoxic agent.
However, its excellent result in protecting pericytes from hypoxia-
induced-damage provides a sign of its distinct bioactivity, which
possibly derives from different constituents. In observing this fact,
another idea that can be generated is to mix D01 and D02 in the correct
ratio to produce a synergistic therapy on the tumour microenvironment.
By that strategy, it may strengthen each other's potency and provide a
better approach to eliminate cancer. Nevertheless, this hypothesis needs
to be proven by identifying the respective pure compounds and how they
interact with each other in the tumour microenvironment.
5. Conclusion
From a scientiﬁc perspective, many useful natural lead compounds
await discovery as less than 10% of the world's biodiversity has been
evaluated for potential biological activity (Cragg and Newman, 2005).
However, the challenge to access, standardize and test this natural
chemical diversity based on an analytical chemistry and pharmacology
approach needs to be addressed before any claim is conﬁrmed. As a
complementary drug whose perspective is to beneﬁt from a synergistic
effect of multiple compounds, a combinatorial approach to co-administer
both natural drug and conventional drug may also contribute to a novel
strategy to deliver a better treatment.
From the results of the cell viability and wound healing assays of
HUVECs and pericytes, the potency to develop D01 as an anti-
proliferative and anti-migratory compound for preventing cancer
angiogenesis is a rational option to explore. Albeit the unclarity of
analysis of D01 pure compounds, most of them could be classiﬁed as
modiﬁed terpenoids which are possibly the reason of their putative anti-
angiogenic activities. Though it may not be as strong as Taxol at the same
concentrations, D01 would be a good candidate as a complementary drug
alongside certain existing anti-cancer drugs e.g. Taxol, Vincristine,
Vinblastine. The administration of propolis as an adjuvant to reduce the
complications of chemotherapy and increase the effectiveness of the
treatment has been assessed by some studies (Padmavathi et al., 2006;
Suzuki et al., 2002; Takara et al., 2007). The application of propolis as a
chemotherapy adjuvant is also supported by the evidence that propolis
administration to humans and rats is generally safe and does not induce
detectable adverse effects (Jasprica et al., 2006; Watanabe et al., 2011).
The idea is also strengthened by D02's protective activity towards peri-
cytes which can be administered together with D01 to produce a further
synergistic effect for tackling tumour angiogenesis.
It is interesting to note that both D01 and D02 have distinct activities
toward vascular and cancer cells, even though they are produced from
the same colony. Furthermore, both samples also have a slight difference
of component although most of them are putatively under the class of
terpenes and terpenoids. The unique characteristic of D01 and D02, in
both chemical and pharmacological perspectives, has emerged new
questions for understanding their exact mechanism and signalling on
vascular and cancer cells. The outstanding questions that remain are:
how can this difference happen despite being made by the same colony?
Does the colony make the component of each sample intentionally11different? Does the difference of the component relate to their distinct
bioactivities? The answers to these questions can lead to a better un-
derstanding on how to harness, not only these two speciﬁc samples, but
propolis in general as a source of novel therapy. In the later stage, the
elucidation of their mechanisms of action can be enhanced using mo-
lecular docking and chemogenomic techniques in order to predict the
interaction between the pure compounds and their speciﬁc targets.
Nevertheless, an exact identiﬁcation of their pure compounds is
mandatory before conducting such studies. Although the components of
the two samples responsible for their biological activities were not fully
investigated in this research, present study opens a new perspective for
further investigation. In conclusion, a continuation of this research is
necessary to further develop both propolis samples to the stage of drug
discovery, more speciﬁcally for the medical world, the economy and the
society of Indonesia.
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